Neurocrine Biosciences: Ambitious Contender In The CNS Space

Jan. 25, 2023 12:55 PM ETNeurocrine Biosciences, Inc. (NBIX)KRTX, VYGR
Sean Daly profile picture
Sean Daly


  • Expect strong Neurocrine Biosciences, Inc. Q4 results on February 6, 2023.
  • Two important pipeline results regarding congenital adrenal hyperplasia and focal onset seizures will be coming this February.
  • The FDA accepted Neurocrine Biosciences' sNDA for valbenazine as a treatment for chorea associated with Huntington's disease in December, and the verdict is due out before August 20, 2023.
  • Free cash flow from Ingrezza TD should support the pipeline without need for further dilutive financing.
  • Success on all three fronts -- CAH, seizures, and chorea -- could double Neurocrine Biosciences, Inc. stock within the year. According to one model, the ticker is 60% undervalued.

Medicine and health. Cubes lie on the table among the pills and imitation of the brain. The text on the dice - CHOREA

Andrei Askirka/iStock via Getty Images

Last quarter, Neurocrine Biosciences, Inc. (NASDAQ:NBIX) saw a clear acceleration in its core Ingrezza tardive dyskinesia franchise. Q3 net product sales increased +31.3% year-over-year to $379.3M, with net sales of Ingrezza specifically amounting to $376M. The company even raised

NBIX --Discounted Cash Flow Model

NBIX --Discounted Cash Flow Model (SimplyWallStreet)

This article was written by

Sean Daly profile picture
Sean Daly writes on ETFs, biotech and FINTECH solutions in the banking space.  He teaches international finance and financial risk management at Pace University and was a visiting lecturer at Princeton University from 2005 to 2009.  He was educated at Columbia University.  He has also written extensively on real estate and  economic development, exploring issues as diverse as Chinese urbanization, CMI multilateral currency swap arrangements, energy geopolitics, and Asia's sovereign wealth funds.    Global strategy and private equity background. Equity Approach: long/short, event-driven, with a focus on small cap biotech and the emerging markets.

Disclosure: I/we have a beneficial long position in the shares of NBIX either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.

Recommended For You


To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.